A portal vein injection model to study liver metastasis of breast cancer

Journal of Visualized Experiments

Volumn 2016, Issue 118, 2016, Pages 1-10

  Goddard, Erica T ^a   Fischer, Jacob ^a   Schedin, Pepper ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Breast cancer; Cancer research; Intraportal injection; Issue 118; Liver metastasis; Mouse model; Portal vein; Survival surgery

Indexed keywords

ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; FEMALE; HEPATIC PORTAL VEIN; HUMAN; LIVER TUMOR; METASTASIS; MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PORTAL VEIN;

EID: 85008631602     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/54903     Document Type: Article

References (79)

1. Hess, K. R. et al. Metastatic patterns in adenocarcinoma. Cancer. 106, 1624-1633 (2006).
2. Berman, A. T., Thukral, A. D., Hwang, W. T., Solin, L. J., & Vapiwala, N. Incidence and patterns of distant metastases for patients with earlystage breast cancer after breast conservation treatment. Clin Breast Cancer. 13, 88-94 (2013).
3. Savci-Heijink, C. D. et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 150, 547-557 (2015).
4. Gerratana, L. et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 32, 125-133 (2015).
5. Bonotto, M. et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 19, 608-615 (2014).
6. Wyld, L. et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 89, 284-290 (2003).
7. Tarhan, M. O. et al. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival. Clin Exp Metastasis. 30, 201-213 (2013).
8. Tseng, L. M. et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 60, 290-294 (2013).
9. Liu, X. H., Man, Y. N., Cao, R., Liu, C., & Wu, X. Z. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. Curr Med Res Opin. 30, 1017-1024 (2014).
10. Ahn, S. G. et al. Prognostic factors for patients with bone-only metastasis in breast cancer. Yonsei medical journal. 54, 1168-1177 (2013).
11. Purushotham, A. et al. Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship. Eur J Cancer. 50, 1697-1705 (2014).
12. Karimi, A., Delpisheh, A., Sayehmiri, K., Saboori, H., & Rahimi, E. Predictive factors of survival time of breast cancer in kurdistan province of Iran between 2006-2014: a cox regression approach. Asian Pac J Cancer Prev. 15, 8483-8488 (2014).
13. Chambers, A. F., Groom, A. C., & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563-572 (2002).
14. Pantel, K., & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature reviews. Cancer. 4, 448-456 (2004).
15. Joyce, J. A., & Pollard, J. W. Microenvironmental regulation of metastasis. Nat Rev Cancer. 9, 239-252 (2009).
16. Luzzi, K. J. et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 153, 865-873 (1998).
17. Cameron, M. D. et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541-2546 (2000).
18. Psaila, B., & Lyden, D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 9, 285-293 (2009).
19. Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 17, 867-874 (2011).
20. Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 17, 816-826 (2015).
21. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820-827 (2005).
22. Erler, J. T. et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35-44 (2009).
23. Zhao, L. et al. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology. 57, 829-839 (2013).
24. Peinado, H., Lavotshkin, S., & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 21, 139-146 (2011).
25. Van den Eynden, G. G. et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 73, 2031-2043 (2013).
26. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537-549 (2003).
27. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature. 436, 518-524 (2005).
28. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature. 459, 1005-1009 (2009).
29. Ogba, N. et al. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast cancer research: BCR. 16, 489 (2014).
30. Coffelt, S. B. et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345-348 (2015).
31. Kitamura, T., Qian, B. Z., & Pollard, J. W. Immune cell promotion of metastasis. Nat Rev Immunol. 15, 73-86 (2015).
32. Zhang, Q. et al. CCL5-Mediated Th2 Immune Polarization Promotes Metastasis in Luminal Breast Cancer. Cancer Res. 75, 4312-4321 (2015).
33. Ruffell, B., & Coussens, L. M. Macrophages and therapeutic resistance in cancer. Cancer Cell. 27, 462-472 (2015).
34. Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7, 10501 (2016).
35. Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 352, aad3018 (2016).
36. Dexter, D. L. et al. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 38, 3174-3181 (1978).
37. Aslakson, C. J., & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405 (1992).
38. Fantozzi, A., & Christofori, G. Mouse models of breast cancer metastasis. Breast Cancer Res. 8, 212 (2006).
39. Pulaski, B. A., & Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58, 1486-1493 (1998).
40. Doornebal, C. W. et al. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res. 73, 353-363 (2013).
41. Derksen, P. W. et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 10, 437-449 (2006).
42. Pravtcheva, D. D., & Wise, T. L. Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool. 281, 43-57 (1998).
43. Lin, S. C. et al. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 64, 3525-3532 (2004).
44. Basse, P., Hokland, P., Heron, I., & Hokland, M. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Natl Cancer Inst. 80, 657-665 (1988).
45. Campbell, J. P., Merkel, A. R., Masood-Campbell, S. K., Elefteriou, F., & Sterling, J. A. Models of bone metastasis. J Vis Exp., e4260 (2012).
46. Balathasan, L., Beech, J. S., & Muschel, R. J. Ultrasonography-guided intracardiac injection: an improvement for quantitative brain colonization assays. The American journal of pathology. 183, 26-34 (2013).
47. Werbeck, J. L. et al. Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo. Vet Pathol. 51, 868-881 (2014).
48. Zhou, H., & Zhao, D. Ultrasound imaging-guided intracardiac injection to develop a mouse model of breast cancer brain metastases followed by longitudinal MRI. J Vis Exp. (2014).
49. Rajendran, S. et al. Murine bioluminescent hepatic tumour model. J Vis Exp. (2010).
50. Soares, K. C. et al. A preclinical murine model of hepatic metastases. J Vis Exp., 51677 (2014).
51. Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 204, 3037-3047 (2007).
52. Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 325, 612-616 (2009).
53. Levy, L. et al. Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology. 4, e998469 (2015).
54. Higashijima, J. et al. Effect of splenectomy on antitumor immune system in mice. Anticancer Res. 29, 385-393 (2009).
55. Thalheimer, A. et al. The intraportal injection model: a practical animal model for hepatic metastases and tumor cell dissemination in human colon cancer. BMC Cancer. 9, 29 (2009).
56. Limani, P. et al. Selective portal vein injection for the design of syngeneic models of liver malignancy. Am J Physiol Gastrointest Liver Physiol. 310, G682-688 (2016).
57. Lelekakis, M. et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 17, 163-170 (1999).
58. Pulaski, B. A., & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Current protocols in immunology/edited by John E. Coligan… [et al.]. Unit 20 22 (2001).
59. Mahoney, K. H., Miller, B. E., & Heppner, G. H. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J Leukoc Biol. 38, 573-585 (1985).
60. Rak, J. W., McEachern, D., & Miller, F. R. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia. Br J Cancer. 65, 641-648 (1992).
61. Barkan, D. et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70, 5706-5716 (2010).
62. Lyons, T. R. et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med. 17, 1109-1115 (2011).
63. Allott, E. H. et al. Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat. 147, 415-421 (2014).
64. Kim, S. et al. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 15, 960 (2015).
65. Esbona, K. et al. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 18, 35 (2016).
66. Andrade, R. J. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 129, 512-521 (2005).
67. Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 135, 1924-1934, 1934 e1921-1924 (2008).
68. O'Brien, J. et al. Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland. Int J Dev Biol. 55, 745-755 (2011).
69. Adamson, T. W. et al. Assessment of carprofen and buprenorphine on recovery of mice after surgical removal of the mammary fat pad. J Am Assoc Lab Anim Sci. 49, 610-616 (2010).
70. Doornebal, C. W. et al. Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2(+) breast cancer. Pain. 156, 1424-1432 (2015).
71. Fischer, A. H., Jacobson, K. A., Rose, J., & Zeller, R. Paraffin embedding tissue samples for sectioning. CSH Protoc. 2008 (2008).
72. Cardiff, R. D., Miller, C. H., & Munn, R. J. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014, 655-658 (2014).
73. Maller, O. et al. Collagen architecture in pregnancy-induced protection from breast cancer. J Cell Sci. 126, 4108-4110 (2013).
74. Martinson, H. A., Jindal, S., Durand-Rougely, C., Borges, V. F., & Schedin, P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Cancer. (2014).
75. Day, C. P. et al. "Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. PLoS One. 9, e109956 (2014).
76. Schafer, M., & Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 9, 628-638 (2008).
77. Kuraishy, A., Karin, M., & Grivennikov, S. I. Tumor promotion via injury- and death-induced inflammation. Immunity. 35, 467-477 (2011).
78. Herreros-Villanueva, M., Hijona, E., Cosme, A., & Bujanda, L. Mouse models of pancreatic cancer. World J Gastroenterol. 18, 1286-1294 (2012).
79. Johnson, R. L., & Fleet, J. C. Animal models of colorectal cancer. Cancer Metastasis Rev. 32, 39-61 (2013).